Drug Trial Radar · NCT07190885
A Pharmacokinetic Study of YN001 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 18, 2025
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Beijing Inno Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-center, open-label study designed to evaluate the pharmacokinetics (PK), safety, and immunogenicity following a single dose administration in healthy adult volunteers.
Conditions
- Healthy Volunteers
Interventions
YN001Drug
YN001 administered via intravenous infusion. Participants will receive either 20 mg (Cohort 1) or 40 mg (Cohort 2).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the maximum plasma concentration (Cmax) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
- To evaluate the time to reach maximum plasma concentration (Tmax) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
- To evaluate the area under the concentration-time curve from time 0 to last measurable concentration (AUC0-t) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
- To evaluate the area under the concentration-time curve extrapolated to infinity (AUCinf) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
- To evaluate the terminal elimination rate constant (λz) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
- To evaluate the plasma half-life (T1/2) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
- To evaluate the clearance (CL) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
- To evaluate the volume of distribution (Vd) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.